CMChunxuan Ma

Chunxuan Ma

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Chunxuan Ma has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cerebrospinal Fluid Over Plasma Links Analytes to Cognitive Decline in Older Adults at Risk for Alzheimer's Disease

    by Jagan A. Pillai, Audrey Zhu, Chunxuan Ma, Ming Wang, Yifan Yang, Lynn M. Bekris, Maria Khrestian, Frank P. DiFilippo, Mikhail Nasrallah, Aaron Burberry, et al.

    Objective: To identify inflammatory analytes in cerebrospinal fluid (CSF) and plasma associated with cognitive decline in cognitively normal (CN) older adults at risk for Alzheimer's disease (AD). Methods: In a longitudinal study of 118 CN older adults (65–80 years, 54% APOE ε4, 26% preclinical AD), 1331 CSF and 1501 plasma analytes were quantified at baseline and 2‐year follow‐up using SomaLogic, with key inflammatory findings validated on the Luminex platform. Linear models (Limma), adjusted for age, sex, APOEε4 , and amyloid‐positive status, identified pathology‐associated analytes. Co‐expression network and multivariable modeling defined hub analytes and enriched pathways. To assess robustness, a targeted panel of 94 inflammation‐related analytes was analyzed using best subsets regression to derive parsimonious models based on adjusted R 2 improvement (≥ 0.01) and ≥ 5 observations per predictor. Subgroup analyses by amyloid and APOE ε4 status were performed, and a two‐stage elastic‐net approach additionally validated analyte selection. Results: CSF proteomics revealed stronger APOEε4 and amyloid‐associated analyte signatures than plasma. Forty‐four CSF analytes were co‐regulated by APOEε4 and amyloid‐positive status, forming central network hubs (e.g., EFNB2, NPTN, UNC5D) enriched in axon guidance, synaptic signaling, and extracellular matrix pathways. In contrast, inflammatory analytes including eotaxin‐1 and IL‐17 pathway‐related molecules were associated with longitudinal cognitive decline, with stronger effects observed in females. Eotaxin‐1 demonstrated the most consistent predictive performance across analytic methods, subsets, and assay platforms, whereas network hub analytes were not predictive of cognitive outcomes. Interpretation: CSF reflects strong APOEε4 /amyloid related proteomic network alterations linked to cognitive decline, while plasma provides weaker but complementary signals. CSF inflammatory signaling, particularly eotaxin‐1, may serve as a correlate of longitudinal cognitive decline in cognitively normal older adults at risk for AD.


  • Open Access

    Evaluating a Tailored Web-Based eHealth Intervention for Symptom Management in Couples Managing Prostate Cancer During the COVID-19 Pandemic: Randomized Clinical Trial

    by Lixin Song, Christine Rini, Yuexia Zhang, Chunxuan Ma, Laurel Northouse, Matthew E Nielsen, Xianming Tan, Ronald C Chen

    Background: Prostate cancer (PCa) is the most common nonskin cancer among men. Although treatments achieve excellent survival for localized PCa, long-lasting complications significantly diminish patients’ quality of life (QOL) across physical, sexual, psychosocial, and general symptom domains. Because these effects also profoundly impact intimate partners, often reducing partners’ QOL as much as or more than patients’ QOL, supportive care must address the needs of both members of the couple. Objective: This study evaluated the efficacy of the Prostate Cancer Education and Resources for Couples (PERC) eHealth intervention in improving outcomes for patients and their partners. Methods: We enrolled 280 dyads (560 individuals) consisting of patients with localized PCa who recently completed treatment and their partners through the North Carolina Cancer Registry. Dyads were randomized to PERC or a control group that received access to the National Cancer Institute prostate cancer website. PERC dyads completed a nurse-led orientation and received monthly follow-ups. The platform has the following three components: (1) 11 interactive modules with postsession assignments on QOL, symptom management, and cancer communication; (2) a moderated online forum providing professional and peer support; and (3) a resource toolbox containing scientific publications related to PCa care. PERC development was guided by an adapted stress-coping theory and informed by evidence and stakeholder input. Validated questionnaires assessed QOL (Functional Assessment of Chronic Illness Therapy–General [FACT-G] total; primary outcomes), FACT-G subdomains, and symptom and psychosocial measures (secondary outcomes) at baseline and at 4, 8, and 12 months. Multilevel linear mixed models tested intervention effects. Results: The trial was conducted during the COVID-19 pandemic. Among PERC (n=141) and control (n=139) dyads who completed baseline assessments, 221 (78.9%) dyads completed the 12-month follow-up (PERC=106 and control=115). FACT-G total score, subdomains, and overall psychosocial outcomes did not differ significantly between groups over time. Patients assigned to PERC reported better physical QOL (mean difference 0.9, 95% CI –0.1 to 1.9; Cohen d =0.33), less negative illness appraisal (mean difference 0.2, 95% CI 0.0-0.4; Cohen d =0.38), lower pain (mean difference –2.7, 95% CI –5.3 to –0.2; Cohen d =–0.38) at 12 months, and less frequent fatigue across time (mean difference –2.1, –95% CI –3.9 to –0.4; Cohen d =–0.23). PERC partners reported less urinary symptom bother at 8 months (mean difference 6.5, 95% CI –1.0 to 14.1; Cohen d =0.44). Conclusions: Although no significant between-group difference was observed in the FACT-G total score, PERC demonstrated exploratory benefits, including improved physical QOL, less fatigue, lower pain, and improved illness appraisal among patients, as well as less urinary bother among partners. These findings suggest that the COVID-19 pandemic may have adversely affected participants’ overall QOL, potentially obscuring changes in the primary outcome, while highlighting targeted benefits that warrant evaluation in larger studies.

  • Open Access

    The Challenges and Strategies of Accrual and Retention During COVID-19 in a Randomized Controlled Trial Testing A Dyad-focused eHealth Intervention (Preprint)

    by Chunxuan Ma, Rachel H. Adler, Daria B. Neidre, Ronald C. Chen, Laurel L. Northouse, Christine Rini, Xianming Tan, Lixin Song

    Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Family-based randomized controlled trials (RCT) encounter recruitment and retention challenges. Cancer-focused RCTs typically recruit convenience samples from local cancer centers and hospitals. Objective: Our study examined the recruitment and retention of a population-based patient-partner dyad cohort in an RCT testing a dyadic eHealth intervention to improve quality of life in prostate cancer (PCa) patients and their partners. Methods: In this two-arm, parallel-group RCT, men who recently completed treatment for localized PCa statewide were recruited via the North Carolina Central Cancer Registry Rapid Case Ascertainment (RCA) between April 2018 and April 2021, coinciding with the COVID-19 pandemic. Patient-partner dyads underwent baseline assessments and were randomly assigned to the intervention or control groups. Follow-up surveys were conducted at 4-, 8-, and 12 months post-baseline. Descriptive and logistic regression analyses were employed to achieve the study’s aims. Results: Of the 3,078 patients referred from RCA, 2,899 were screened; 357 partners were approached after obtaining eligible patients’ permission; 280 dyads completed baseline assessments and randomized (dyad enrollment rate: 85.11%); and 221 dyads completed the 12-month follow-up (retention rate: 78.93%). Factors associated with retention included race and age. Conclusions: Despite the negative impact of the pandemic, we successfully recruited enough patient-partner dyads to test our RCT hypotheses. Our recruitment and retention rates were equivalent to or higher than those in most dyadic intervention studies. A well-functioning research team and specific strategies (e.g., eHealth intervention, Internet phone, and online surveys) facilitated the recruitment and retention of PCa patients and their partners during the unprecedented pandemic. Clinical Trial: Clinicaltrial.gov ID: NCT03489057.


  • Open Access

    Challenges and Approaches to Recruitment for and Retention in a Dyad-Focused eHealth Intervention During COVID-19: Randomized Controlled Trial (Preprint)

    by Chunxuan Ma, Rachel H Adler, Daria B Neidre, Ronald C Chen, Laurel L Northouse, Christine Rini, Xianming Tan, Lixin Song

    BACKGROUND Family-based randomized controlled trials (RCTs) encounter recruitment and retention challenges. Cancer-focused RCTs typically recruit convenience samples from local cancer centers and hospitals. OBJECTIVE This study aimed to examine the recruitment and retention of a population-based, patient-partner dyad cohort in an RCT testing a dyadic eHealth intervention to improve the quality of life in patients with prostate cancer and their partners. METHODS In this 2-arm, parallel-group RCT, men who recently completed treatment for localized prostate cancer statewide were recruited through North Carolina Central Cancer Registry rapid case ascertainment between April 2018 and April 2021, coinciding with the COVID-19 pandemic. Patient-partner dyads underwent baseline assessments and were randomly assigned to either the intervention or control groups. Follow-up surveys were conducted at 4, 8, and 12 months after baseline. Descriptive and logistic regression analyses were used to achieve the study’s aims. RESULTS Of the 3078 patients referred from rapid case ascertainment, 2899 were screened. A total of 357 partners were approached after obtaining the eligible patients’ permission, 280 dyads completed baseline assessments and were randomized (dyad enrollment rate: 85.11%, 95% CI 81.3%-88.9%), and 221 dyads completed the 12-month follow-up (retention rate: 78.93%, 95% CI 74.2%-83.7%). Regarding the factors associated with retention, compared with White participants, people self-reporting as “other races” (including American Indian, Asian, and multiracial) were more likely to drop out of the study (odds ratio 2.78, 95% CI 1.10-7.04), and older participants were less likely to withdraw (odds ratio 0.96, 95% CI 0.92-0.99). CONCLUSIONS Despite the negative impact of the pandemic, we successfully recruited enough patient-partner dyads to test our RCT hypotheses. Our recruitment and retention rates were equivalent to or higher than those in most dyadic intervention studies. A well-functioning research team and specific strategies (eg, eHealth intervention, internet phone, and online surveys) facilitated the recruitment and retention of patients with prostate cancer and their partners during the unprecedented pandemic. CLINICALTRIAL ClinicalTrials.gov NCT03489057; https://clinicaltrials.gov/study/NCT03489057 INTERNATIONAL REGISTERED REPORT RR2-https://doi.org/10.1186/s13063-021-05948-5